On November 17, 2017, UACT submitted written comments the US Food and Drug Administration’s request for comments concerning, “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” The call for comments followed a public meeting hosted by the FDA in July 2017. The comments submitted by UACT call for the FDA to support three measures that would help increase access to cancer treatments and other medical technologies.  These measures include compulsory licensing as leverage for the proposed Medicare negotiation powers, the FDA to require greater transparency of R&D costs as a condition of marketing approval, and support for feasibility studies to explore businessRead More →

Each year, the Graduate Institute Geneva compiles the list of “300 Women Leaders in Global Health.” The list was created to “showcase female leadership in global health,” and nominations are gathered from peers to recognize women’s contributions to global health policies and initiatives. UACT is pleased to highlight the women included on the list who are involved with guiding UACT’s mission and work. Five of the incredible women included in the “300 Women Leaders in Global Health” are members of UACT’s leadership, including two members of the Board of Directors, two members of the Expert Advisory Board, as well as our Acting Director. Nominees from our BoardRead More →

By Julie Chmelikova There are currently 28 EU member states, yet their health care systems vary substantially and are based on national policies. Reimbursement models, health care expenditures, availability of resources and accessibility of drugs are just some of the aspects of health care where major differences occur. Access to cancer drugs is an especially pressing issue that demonstrates vividly the differences in access to health care across the EU. The inequality is evident for example in the case of Poland, Hungary and Slovakia, where patients do not have access to many innovative cancer drugs, such as Kadcyla (breast cancer), Jevtana (prostate cancer), Dacogen (acuteRead More →